Dopamine is involved in multiple neural
Introduction
Dopamine is implicated in various CNS functions including motor control, emotional processing, learning and reinforcement, and cognitive attention Holland and Gallagher, 1999; Di Chiara, 2002; Wise, 2004; Everitt and Robbins, 2005) . Dopaminergic neurons are located in several midbrain structures in mammals, such as substantia nigra pars compacta and ventral tegmental area, and innervate the striatum, the prefrontal cortex, and limbic structures such as the amygdala (Dahlström and Fuxe, 1964; Fallon and Moore, 1978) . Dopamine exerts its functions by binding to two distinct classes of G-proteincoupled receptors (GPCRs), namely the D 1 receptors comprising the D 1 and D 5 subtypes and the D 2 receptors comprising the D 2 , D 3 , and D 4 subtypes (Missale et al., 1998) . D 1 and D 2 receptors mediate specific functions through distinct intracellular signaling cascades (Missale et al., 1998; Nicola et al., 2000; Greengard, 2001; Nestler, 2005) and different patterns of expression (Goldman-Rakic, 1996; Gerfen, 2004) . Furthermore, various neural pathways such as those of glutamate, serotonin, and acetylcholine as well as humoral factors such as adenosine interact with dopaminergic pathways and critically modulate D 1 and D 2 receptor signaling (Svenningsson et al., 2004) . Elucidating neural and humoral networks surrounding dopaminergic neurons and regulation is therefore important for understanding functions of the dopaminergic nervous system as well as neurological and psychiatric disorders caused by its dysfunction.
We have been studying the physiological roles of prostagladins (PGs). PGs including PGD 2 , PGE 2 , PGF 2␣ , PGI 2 , and thromboxane A 2 (TXA 2 ) are a family of lipid mediators that are widely formed throughout our body and elicit versatile functions in a variety of processes including vascular homeostasis, inflammation, and reproduction . PGs bind to eight types and subtypes of GPCRs to exert their actions; they are the PGD receptor (DP), the four subtypes of PGE receptor (EP 1 , EP 2 , EP 3 , and EP 4 ), the PGF receptor (FP), the PGI receptor (IP), and the TXA receptor (TP). Because of their specific localization and intracellular signaling pathways, each receptor can mediate a unique profile of actions in the body . The function of PGs in CNS has thus far been studied mostly in relation to sickness behaviors (Elmquist et al., 1997; Turnbull and Rivier, 1999) . Our previous studies on each EP subtype-deficient mice individually revealed that EP 3 mediates febrile responses, and that both EP 1 and EP 3 are required for the neuroendocrine stress response (Ushikubi et al., 1998; Matsuoka et al., 2003) . EP 1 -deficient mice further exhibit enhanced aggression and impaired cliff avoidance, indicating that the PGE 2 -EP 1 signaling controls impulsive behaviors under environmental and social stress . Although these mice show enhanced dopamine turnover in the striatum and frontal cortex and administration of dopamine receptor antagonists suppresses their impulsivity, they do not show hyperlocomotion. Here, we have analyzed the role of EP 1 in the dopaminergic signaling in the striatum and related behaviors. Our data suggest that PGE 2 is formed in response to dopamine receptor stimulation in the striatum and regulates signaling and function of both D 1 and D 2 receptors via EP 1 .
Materials and Methods
Mice. Mice lacking the Ptger1 gene encoding EP 1 (EP 1 Ϫ/Ϫ ) were generated and backcrossed Ͼ10 generations to the C57BL/6CrSlc background as described previously . Male littermates 2-3 months of age having EP 1 Ϫ/Ϫ and wild-type genotypes derived from the same EP 1 ϩ/Ϫ parents were used for each comparison group in all the experiments, except those in Figure 6 and supplemental Figure 2 (available at www.jneurosci.org as supplemental material), in which agematched, male C57BL/6CrSlc mice (SLC, Shizuoka, Japan) were used as the wild-type control. All animal care and use was in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and was approved by the Institutional Animal Care and Use Committee of Kyoto University Graduate School of Medicine or that of Kurume University Graduate School of Medicine.
In situ hybridization and immunohistochemistry. In situ hybridization was performed using the standard method with an 35 S-labeled antisense riboprobe matching the entire length of mouse EP 1 cDNA as described previously (Furuyashiki et al., 1999) . Control slides were incubated with the radioactive probe in the presence of a 200 times excess amount of nonradioactive riboprobe from the same template. Immunohistochemistry was performed as described previously (Lee et al., 1997) with modifications. Under deep anesthesia with sodium pentobartiturate injected intraperitoneally (60 mg/kg; Dainippon Pharmaceutical, Osaka, Japan), mice were perfused transcardially with 0.9% sodium chloride in 5 mM phosphate buffer (PBS; pH 7.4), followed by 4% formaldehyde in 0.1 M sodium phosphate, pH 7.4. After incubation in 30% sucrose in PBS for cryoprotection, brains were cut at coronal planes at 20 m thickness on a microtome frozen at Ϫ20°C. The brain sections were incubated for 36 h at 4°C with a rabbit polyclonal antibody to EP 1 (1:250; 101740; Cayman Chemical, Ann Arbor, MI), followed by incubation with HRPconjugated goat anti-rabbit IgG (1:200 dilution; 111-035-144; Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature. The incubation with antibodies was performed in PBS containing 0.25% Triton X-100, 0.25% -carrageenan, 10% goat serum, and 1% BSA, and followed by a rinse with PBS containing 0.1% Triton X-100. For double staining, the sections were further incubated overnight at 4°C with a guinea pig polyclonal antibody to preprodynorphin (PPD) (1:200 dilution; AB5519, Chemicon, Temecula, CA) or that to preproenkephalin (PPE) (1:200 dilution; a gift from Dr. Takeshi Kaneko, Kyoto University, Kyoto, Japan) (Lee et al., 1997) . Signals for EP 1 and PPD/PPE were visualized with fluorescein-conjugated Tyramide (PerkinElmer, Boston, MA) and Cy3-conjugated anti-guinea pig IgG antibody (1:500 dilution; 706-165-148; Jackson ImmunoResearch), respectively. Fluorescence images were acquired on a LSM510 laser-scanning confocal microscope (Zeiss, Oberkochen, Germany). The specificity of the EP 1 signal was examined by blocking with an epitope peptide as well as on tissues from EP 1 -deficient mice (see Results).
Perfusion of striatal slices and quantification of PGE 2 . Striatal slices of 300 m thickness were prepared from wild-type mice as described previously (Nishi et al., 1997) . The slices were loaded onto the chambers and perfused with Krebs-HCO 3 Ϫ buffer (124 mM NaCl, 4 mM KCl, 26 mM NaHCO 3 , 1.5 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 1.5 mM MgSO 4 , 10 mM D-glucose, pH 7.4) saturated with 95% O 2 and 5% CO 2 at a flow rate of 0.5 ml/min. Some animals and their slices were treated with indomethacin, a cyclooxygenase (COX) inhibitor that blocks the production of PGs. For the indomethacin-treated controls, slices were prepared from wildtype mice administered with 5 mg/kg indomethacin (Nacalai Tesque, Kyoto, Japan) intraperitoneally 30 min before decapitation, and were perfused with Krebs-HCO 3 Ϫ buffer containing 1 mM indomethacin. After equilibration for 60 min, the perfusing buffer was changed to Krebs-HCO 3 Ϫ buffer containing either vehicle or indicated concentrations of 6-chloro-2,3,4,5-tetrahydro-1-phenyl-1 H-3-benzazepine hydrobromide (SKF81297) (Sigma-Aldrich, St. Louis, MO), or quinpirole (SigmaAldrich), or both. After the slices were exposed to the drug-containing buffer, perfusates were collected for 5 min in chilled tubes containing 600 l of ethanol and 700 l of 0.1N hydrochloric acid. [5,6,8,11,12,14,15(n)- 3 H]PGE 2 (7.4 TBq/mmol; Amersham Biosciences, Piscataway, NJ) (10,000 cpm) was then added to the samples as a tracer for monitoring recovery, and the samples were centrifuged at 3000 ϫ g for 10 min at 4°C. The supernatants were applied to preconditioned Sep-Pak plus cartridges (WAT0200515; Waters, Milford, MA), which were washed serially with 15% ethanol, petroleum ether, and, finally, 5 ml of methyl formate as described previously (Powell, 1980) . The methyl formate fraction was recovered in a glass vial and stored at Ϫ80°C until use. Methyl formate was then evaporated, and the residues were suspended in 150 l of water/methyl formate (80:20, v/v) . Samples were then subjected to HPLC on a Cosmosil 5C 18 column (4.6 ϫ 150 mm; Nacalai Tesque) with water/acetonitrile/acetic acid (67:33:0.01, v/v/v). Fractions corresponding to the elution position of authentic PGE 2 were collected, and, after evaporation, residues were suspended in 200 l volume of an assay buffer (0.1 M phosphate buffer, pH 7.5, containing 0.9% bovine serum albumin and 0.5% kathon). The PGE 2 -like immnoreactivity was then determined using an enzyme immunoassay (EIA) kit (GE Healthcare, Piscataway, NJ).
Behavioral analysis. Acute and chronic psychostimulant effects of cocaine were tested as described previously (Hikida et al., 2001) . For acclimation to the injection procedure, mice were injected intraperitoneally with saline and placed in a transparent, plastic test chamber (22 ϫ 32 ϫ 13.5 cm 3 ) for 10 min once a day on days 1 and 2. From day 3 to day 7, mice were administered cocaine (10 or 20 mg/kg; Takeda Pharmaceutical, Osaka, Japan) or vehicle (0.9% sodium chloride) and placed in the test chamber for 10 min once a day. For SKF81297-induced hyperlocomotion (Xu et al., 1994) , mice were habituated to a transparent, plastic test chamber (46 ϫ 46 ϫ 30.3 cm 3 ) for 1 h. They then received intraperitoneal injection of SKF81297 (2.5 or 5 mg/kg) or vehicle (0.9% sodium chloride) and were immediately returned to the test chamber for an additional 1 h observation period. Locomotor activity was measured based on interruption of infrared beams (Melquest, Toyama, Japan). Raclopride-induced catalepsy was measured as described previously (Pertwee, 1972) . Mice were injected intraperitoneally with raclopride (0.25, 0.5, 1, and 2 mg/kg; Sigma-Aldrich) or vehicle (0.9% sodium chloride). Behavior was video-recorded for 5 min from 30 min after drug injection, and the duration of catalepsy was determined post hoc. Catalepsy was defined as the total motionless time on the wire ring. All behavioral tests were performed and analyzed by experimenters blinded to the mouse genotype. A total volume of intraperitoneal injection was set at 8 ml/kg by adjusting drug concentrations and matched across individuals in the same comparison.
Whole-animal studies. Mice were injected intraperitoneally with vehicle (0.9% sodium chloride), cocaine (10 mg/kg), or SKF81297 (2.5 mg/kg) at 15 min before decapitation. After decapitation, the heads of mice were immediately immersed in liquid nitrogen for 30 s. Rostral parts of the frozen heads were cut to the level of the striatum on dry ice, and striatal tissues were punched out and stored at Ϫ80°C until use. For quantification of PGE 2 , frozen striata were weighed, and extracted by homogenization of the tissues in ethanol containing 0.1 M hydrochloric acid. The extracts were then mixed with a tracer of [ 3 H]PGE 2 and subjected to quantification. Alternatively, frozen striata were used for analysis of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) phosphorylation as described below.
Analysis of DARPP-32 phosphorylation. Experiments were performed as described previously (Nishi et al., 1997) . After decapitation, the brain was rapidly removed, and coronal striatal slices were prepared at 350 m thickness using a vibrating blade microtome, VT1000S (Leica Microsystems, Nussloch, Germany). The slices were preincubated at 30°C for 60 min in Krebs-HCO 3 Ϫ buffer saturated with 95% O 2 and 5% CO 2 , and were incubated with drugs as specified in each experiment. ONO-DI-004 was obtained from Ono Pharmaceutical (Osaka, Japan). To terminate the incubation, slices were frozen on dry ice, and stored at Ϫ80°C until use. For immunoblot, the tissues were sonicated in boiling 1% SDS, and boiled for 10 min. Each sample of 100 g protein was subjected to SDS-PAGE (10% polyacrylamide gels), and separated proteins were transferred to nitrocellulose membranes (Nishi et al., 1997) . The membranes were incubated with mAb-23, a monoclonal antibody to Thr34-phosphorylated DARPP-32 (1:750 dilution) (Snyder et al., 1992) . The membrane was then incubated with a goat anti-mouse Alexa 680-linked IgG (1:5000; Invitrogen, Eugene, OR) or a goat antimouse IRDye 800-linked IgG (1:5000; Rockland, Gilbertsville, PA). Antibody binding was quantified with the use of an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). For each experiment, values were normalized to those of control slices without D 1 or D 2 stimulation. To determine the total amount of DARPP-32 in samples, C24-5a monoclonal antibody to DARPP-32 (1:22,500 dilution) (Hemmings et al., 1984) , which is not phosphorylation state-specific, was used for reblotting the membrane. None of the experimental manipulations in the present study altered the total amount of DARPP-32.
Statistical analysis. All data are shown as means Ϯ SEM. Comparison of two groups was analyzed using unpaired two-tailed Student's t test. One-way or two-way ANOVA was performed for each comparison followed by Tukey's or Bonferroni's post hoc tests for evaluation of pairwise group differences. A value of p Ͻ 0.05 was considered statistically significant. The analyses were performed by Prism 4.0 software (GraphPad, San Diego, CA).
Results

EP 1 is expressed in both D 1 -and D 2 -containing neurons in the striatum
We first examined expression and localization of EP 1 in the striatum. In situ hybridization using radioactive EP 1 antisense riboprobe exhibited silver grains diffusely distributed over cell bodies of a large number of cells in both ventral and dorsal striatum, namely the nucleus accumbens (NAc) and the caudate putamen (CPu). The size and shape of these cells indicate that they are striatal neurons. Most of the grains over these cells were abolished by the addition of an excess amount of cold riboprobes (Fig. 1 A) , indicating expression of EP 1 in a majority of neurons in the striatum. We then confirmed this finding by immunostaining. Because the EP 1 immunoreactivity was not of a high amount, we amplified the antigen-antibody complex by the fluoresceinconjugated Tyramide-HRP system. The amplified signals exhibited both diffuse and punctate accumulation in the cytoplasm and proximal processes of a majority of neuron-like cells in the striatum (Fig. 1 B) . In addition, small dot-like signals forming ill defined networks were found over the tissue. Most of the former signals and not the latter were absent in the striatum of EP 1 -deficient mice, suggesting the former represent EP 1 receptor immunoreactivity and the latter background. These results suggested that EP 1 is expressed and present in a number of neurons in the striatum. Over 90% of striatal neurons in rodents are GABAergic projection neurons called medium spiny neurons (MSNs) (Gerfen, 2004) . MSNs are composed of at least two neurochemically distinct populations: those expressing D 1 receptors and PPD and others expressing D 2 receptors and PPE (Gerfen and Young, 1988; Lee et al., 1997) . We therefore conducted double immunohistochemistry for EP 1 and these marker proteins. Double staining for EP 1 and PPD or EP 1 and PPE showed that signals for EP 1 colocalized with those for PPD in some neurons and with those for PPE in other neurons, suggesting that EP 1 is expressed in both PPD-containing D 1 and PPE-containing D 2 MSNs (Fig. 1C) . Quantitative analysis revealed that, in the CPu, EP 1 was expressed in 61% of PPD-positive neurons and 55% of PPE-positive neurons and that, in the NAc, EP 1 was expressed in 71% of PPD-positive neurons and 79% of PPE-positive neurons. Prostaglandin E 2 is produced in striatal slices in response to dopamine receptor stimulation The above findings indicate a possibility that PGE 2 is synthesized and acts on EP 1 in the striatum. To test this hypothesis, we prepared striatal slices from wild-type mice, incubated them with either vehicle, a D 1 agonist, SKF81297, or a D 2 agonist, quinpirole, and examined production of PGE 2 . PGE 2 was extracted from the reaction medium by the use of a Sep-Pak plus cartridge and purified by reversed-phase HPLC, and the PGE 2 -like immunoreactivity in the HPLC fraction was measured by EIA. Authenticity of the PGE 2 -like immunoreactivity was further verified by its decrease in samples obtained from indomethacin-treated mice and incubated with indomethacin. The addition of either SKF81297 or quinpirole significantly increased PGE 2 production in the striatal slices, and this increase was abolished by treatment with indomethacin ( Fig. 2 A, B) . Furthermore, when 3 M each of SKF81297 and quinpirole were added together, the PGE 2 production under this condition was about the sum of those induced by each compound alone (Fig.  2C) . These results suggest that PGE 2 is produced in the striatum in response to both D 1 and D 2 dopamine receptor stimulation and the effect of D 1 and D 2 receptor stimulation is additive.
EP 1 deficiency alters behaviors mediated by dopaminergic signaling in the striatum
To elucidate the function of EP 1 in the striatum in vivo, we used acute cocaine injection. Acute administration of cocaine leads to hyperlocomotion, which is mediated primarily by high synaptic concentration of dopamine because of blockade of dopamine transporters in the striatum (Giros et al., 1996; Pierce and Kalivas, 1997) . We used wild-type and EP 1 -deficient littermates from heterozygous mating, and, after acclimation to injection procedures over 2 d, injected either saline or cocaine (10 or 20 mg/kg) intraperitoneally to these mice. We then tested their locomotor activity in the next 10 min. Cocaine induced hyperlocomotion in wild-type mice in a dose-dependent manner. EP 1 -deficient mice also showed a dose-dependent response to cocaine injection, but hyperlocomotion in these mice was significantly reduced compared with that found in wild-type mice, whereas the locomotor activity on saline injection did not differ between the genotypes (Fig. 3A) . We next examined whether EP 1 is also involved in behavioral sensitization induced by repeated cocaine exposure (Pierce and Kalivas, 1997) . Cocaine (10 mg/kg) was injected intraperitoneally once a day into wild-type and EP 1 -deficient littermates over 5 consecutive days from day 3 to day 7. Daily exposure to cocaine induced sensitization (i.e., a gradual increase in locomotor response to each-day injection of the same dose of cocaine in both wild-type and EP 1 -deficient mice). Furthermore, after 2 week abstinence, both genotypes similarly showed retention of previous sensitization. However, the EP 1 -deficient mice persistently showed significantly less locomotor activity in response to each day cocaine injection over the entire test period (Fig. 3B) . These data suggest that EP 1 is not involved in sensitization to cocaine per se, but participates in elicitation of acute locomotor activity induced by each injection of cocaine. We next injected a D 1 -selective agonist, SKF81297, and examined effects of the EP 1 deficiency on hyperlocomotion induced by D 1 receptor stimulation (Bordi and Meller, 1989) . SKF81297 stimulated locomotion of wild-type mice in a dose-dependent manner, which lasted over 1 h after injection (Fig. 4) . Compared with wild-type mice, EP 1 -deficient mice showed reduced hyperlocomotion in response to Figure 3 . A, Suppression of cocaine-induced hyperlocomotion in EP 1 -deficient mice. Wildtype (ϩ/ϩ) and EP 1 -deficient (Ϫ/Ϫ) mice were injected with either vehicle or 10 or 20 mg/kg cocaine, and locomotor activity was measured over 10 min. The numbers of animals are shown in each column. *p Ͻ 0.05. B, Reduced hyperlocomotion in EP 1 -deficient mice during and after sensitization with repeated cocaine injections. Wild-type (ϩ/ϩ; n ϭ 11) and EP 1 -deficient mice (Ϫ/Ϫ; n ϭ 13) were administered vehicle once a day on days 1 and 2, and then 10 mg/kg cocaine from day 3 to day 7. After 2 weeks of cocaine-free period, the mice were challenged again with 10 mg/kg cocaine on day 20. The locomotor activity was measured over 10 min after each injection. The data at 10 mg/kg in A were adopted from those at day 3 in B. A difference between the genotypes was maintained over the entire testing periods (F (1,4) ϭ 4.925; # p ϭ 0.037). Error bars indicate SEM. . Prostaglandin E 2 is produced in striatal slices in response to dopamine receptor stimulation. Striatal slices were prepared from wild-type mice, perfused with Krebs-HCO 3 Ϫ , and stimulated with either vehicle (control), a D 1 agonist, SKF81297 (10 M) (SKF) (A), or a D 2 agonist, quinpirole (10 M) (Qui) (B), or both (3 M each) (C) for 5 min. The amount of PGE 2 in the perfusates was measured by HPLC-linked enzyme immunoassay kit as described in Materials and Methods. As alternative controls, striatal slices were prepared from indomethacin-injected mice, pretreated with 1 mM indomethacin (Indo) for 60 min, and stimulated with SKF81297 or quinpirole in the continued presence of indomethacin. The numbers of mice used in experiments are shown below each column. Error bars indicate SEM. *p Ͻ 0.05; **p Ͻ 0.01.
SKF81297. The reduction in EP 1 -deficeint mice was statistically significant at the dose of 2.5 mg/kg SKF81297, and became less apparent at the higher dose. These findings indicate that PGE 2 is formed in vivo in the striatum in response to D 1 receptor stimulation and modulates mouse behavior induced by this signaling. To confirm this hypothesis, we treated wild-type mice for 15 min with 2.5 mg/kg SKF81297. Mice were then decapitated, and production of PGE 2 was measured in the striatum punched out from frozen brain. We found that a considerable amount of PGE 2 was present already under basal conditions, but that administration of SKF81297 significantly increased PGE 2 production in this brain region (1.98 Ϯ 0.10 and 2.38 Ϯ 0.10 pg/mg of tissue for control and SKF81297-treated mice, respectively; n ϭ 4 for each group; p ϭ 0.034). A similar treatment with cocaine (10 mg/kg) tended to increase striatal PGE 2 production (2.08 Ϯ 0.08 pg/mg of tissue; n ϭ 4; p ϭ 0.485), but the increase was not statistically significant compared with the vehicle-treated control group.
Given expression of EP 1 in not only D 1 -containing MSNs but also D 2 -containig MSNs, we next examined effects of EP 1 deficiency on a behavioral paradigm induced by a D 2 -selective drug.
To this end, we tested catalepsy induced by a D 2 -selective antagonist, raclopride (Pertwee, 1972) . The addition of raclopride dose-dependently increased immobility time (i.e., catalepsy) in wild-type mice. Although raclopride also dose-dependently increased catalepsy in EP 1 -deficient mice, this response was significantly suppressed in the EP 1 -deficient mice at a dose of 0.25 mg/kg (Fig. 5) .
Extracellular dopamine concentration and ligand binding properties of D 1 and D 2 receptors in the striatum of EP 1 -deficient mice
Neurotransmitter signaling depends on both release of a neurotransmitter from the presynaptic terminal and its binding to the cognate receptor at the postsynaptic site. We analyzed whether EP 1 deficiency affects either of these processes. We first addressed the presynaptic mechanism by measuring the extracellular dopamine content in the ventral striatum of wild-type and EP 1 -deficient mice by microdialysis. The striatum was perfused in vivo with artificial CSF through a microdialysis probe, and the content of dopamine recovered in the effluent was determined. The dopamine content in the dialysates from EP 1 -deficient mice tended to be higher than that from wild-type mice, although there was no statistically significant difference (supplemental Fig. 1 A, available at www. jneurosci.org as supplemental material). The dopamine contents from both genotypes of animals increased after acute cocaine injection (10 mg/kg), the condition in which a significantly reduced hyperlocomotion in EP 1 -deficient mice was observed (Fig. 3) . When normalized to the baseline level before cocaine injection, both groups exhibited a similar rise in the dopamine content (supplemental Fig. 1 B, available at www.jneurosci.org as supplemental material). Although we did not determine absolute concentration of dopamine by equilibrium microdialysis, these results suggest that the EP 1 deficiency did not reduce the synaptic concentration of dopamine compared with that in wild-type mice before and after the cocaine injection.
We next examined ligand binding properties of D 1 and D 2 receptors. The membrane fraction was prepared from the striatum of wild-type and EP 1 -deficient mice, and subjected to radioligand binding assay using (Glowinski and Iversen 1966; List and Seeman, 1981; Charifson et al., 1988 ) (supplemental Fig. 2 (Svenningsson et al., 2004) . Treatment of the slices with SKF81297 increased the level of phospho-Thr34 DARPP-32 (Fig. 6 A) , as previously shown (Nishi et al., 2000) . We then examined the effect of indomethacin on the SKF81297-induced increase in this phosphorylation. Treatment of slices with indomethacin significantly attenuated the SKF81297-induced increase in DARPP-32 Thr34 phosphorylation (Fig. 6 A) , indicating the involvement of endogenously formed PGs in D 1 receptor signaling in the striatum. Consistently, when an EP 1 -selective agonist, ONO-DI-004, was added to the indomethacin-treated slices, ONO-DI-004 restored the SKF81297-induced increase in DARPP-32 Thr34 phosphorylation in a concentration-dependent manner (Fig. 6 B) , whereas ONO-DI-004 alone did not affect DARPP-32 Thr34 phosphorylation (data not shown).
We next examined the effect of SKF81297 on DARPP-32 phosphorylation in EP 1 -deficient mice. Treatment of striatal slices with SKF81297 for 2 min stimulated DARPP-32 Thr34 phosphorylation by approximately threefold in slices from both wild-type and EP 1 -deficient mice. However, the subsequent increase in the Thr34 phosphorylation observed in slices from wildtype mice (by approximately sixfold at 5 min of incubation) was blunted in the slices from EP 1 -deficient mice (Fig. 6C) . These results suggest that SKF81297 stimulates PGE 2 production and that the PGE 2 produced acts on EP 1 to augment D 1 receptor signaling in striatal slices in a positive-feedback manner.
Activation of D 2 receptors is known to suppress DARPP-32 phosphorylation at Thr34 (Nishi et al., 1997) . Consistent with previous reports, treatment of striatal slices with quinpirole decreased DARPP-32 Thr34 phosphorylation in a concentrationdependent manner (Fig. 6 D) . The ability of quinpirole to decrease DARPP-32 Thr34 phosphorylation was significantly attenuated at 10 nM in slices from EP 1 -deficient mice compared with that in slices from wild-type mice, although the effects of quinpirole were similar at higher concentration. These results suggest that the PGE 2 -EP 1 signaling augments D 2 receptor signaling, leading to the suppression of DARPP-32 phosphorylation at Thr34. Together, our data suggest that EP 1 interacts with and augments both D 1 and D 2 receptor signaling in striatal neurons.
Attenuation of cocaine or D 1 agonist-induced DARPP-32
Thr34 phosphorylation in the striatum of EP 1 -deficient mice in vivo To investigate the role of PGE 2 -EP 1 signaling in the regulation of DARPP-32 phosphorylation in vivo, wild-type and EP 1 -deficient mice were treated for 15 min with either cocaine (10 mg/kg) or SKF81297 (2.5 mg/kg), conditions in which stimulation of locomotor activity was attenuated in EP 1 -deficient mice (Figs. 3, 4) . In wildtype mice, administration of both cocaine and SKF81297 significantly increased the level of DARPP-32 Thr34 phosphorylation in the striatum (Fig. 7) . In contrast, in EP 1 -deficient mice, administration of cocaine did not increase and administration of SKF81297 decreased DARPP-32 Thr34 phosphorylation. These results indicate that the PGE 2 -EP 1 pathway plays an essential role in the regulation of dopaminergic signaling in the striatum in vivo.
Discussion
In this study, we used EP 1 -deficient mice and an EP 1 -selective agonist, and examined whether the PGE 2 -EP 1 pathway regulates dopaminergic signaling and function in the striatum. We found that EP 1 is expressed in more than one-half of MSNs in the striatum, that PGE 2 is produced in the striatum in response to stimulation with a D 1 or D 2 agonist, and that the PGE 2 -EP 1 pathway facilitates both D 1 and D 2 signaling as assayed by DARPP-32 Thr34 phosphorylation in vitro in striatal slices. The in vivo relevance of these in vitro findings was underscored by significant attenuation of cocaine-or D 1 agonist-induced hyperlocomotion, D 2 antagonist-induced catalepsy, and cocaine-induced rise of DARPP-32 Thr34 phosphoryla- Thr34 phosphorylation in PG-depleted slices. Striatal slices, prepared from indomethacininjected mice, were incubated with 100 M indomethacin for 60 min to block PG synthesis. In the continued presence of indomethacin, the slices were incubated with 0, 1, 10, or 100 M ONO-DI-004 for 10 min, and SKF81297 (1 M) was added at 5 min of incubation. C, Effects of a D 1 receptor agonist on DARPP-32 Thr34 phosphorylation in striatal slices from wild-type and EP 1 -deficient mice. Striatal slices, prepared from wild-type (BL/6) and EP 1 -deficient (EP 1 Ϫ/Ϫ ) mice, were incubated with 1 M SKF81297 for 0, 2, or 5 min. The numbers of slices used in experiments A-C are shown below each column. D, Effects of a D 2 receptor agonist, quinpirole, on DARPP-32 Thr34 phosphorylation in striatal slices from wild-type and EP 1 -deficient mice. Striatal slices, prepared from wild-type (ϩ/ϩ) and EP 1 -deficient (Ϫ/Ϫ) mice, were incubated with either vehicle or quinpirole (1, 10, 100, or 1000 nM) for 5 min. The data were normalized to values from vehicle-treated slices in each genotype. n ϭ 5-9. Error bars indicate SEM. *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001. tion in situ in the striatum in EP 1 -deficient mice. These findings together strongly suggest that PGE 2 functions as a critical modulator of the dopaminergic system in the striatum. Neurotransmitters such as glutamate, GABA, acetylcholine, and serotonin, neuromodulators such as adenosine, and neuropeptides such as opioids and cholecystokinin are known to regulate dopamine signaling in the striatum. However, the role of prostaglandins has been overlooked. Our present findings suggest that PGE 2 -EP 1 signaling should be added to this growing list of regulators of dopaminergic signaling.
PGs including PGE 2 are produced from arachidonic acid released from the cell membrane by sequential catalysis of COXs and respective isomerases. There are two COX isoforms, COX-1, which is constitutively expressed, and COX-2, which is induced on demand. Berke et al. (1998) found that COX-2 expression is induced by D 1 receptor stimulation in the striatum treated with 6-hydroxydopamine, and suggested that this is part of a genetic adaptation mechanism associated with dopamine depletion. Given that COX-2 expression lasts over hours to days (Smith et al., 2000) , the PGE 2 -EP 1 signaling we found as a physiological regulator of dopamine signaling may function also as a long-term adaptive, paracrine-like mechanism to amplify dopamine signaling in the striatum under some pathological conditions. Why has this seemingly very important modulatory action of PGE 2 been overlooked in the dopamine research field? One plausible reason is that COX inhibitors, such as aspirin and indomethacin, are generally without effects on dopaminergic functions such as motor control. These results suggest a possibility of other PG-dependent pathway(s) opposed to the PGE 2 -EP 1 pathway operating in the striatum. Previously, Horton (1964) reported that intracerebroventricular administration of PGE 2 resulted in catalepsy in cats, and Schwarz et al. (1982) reported that intrastriatal injection of PGE 2 inhibited apomorphine-induced circling in mice. Interestingly, these PGE 2 actions appear to antagonize dopamine signaling, opposite to the facilitatory function of the PGE 2 -EP 1 signaling we found here. This may indicate that other EP subtypes that potentially antagonize the effect of EP 1 are present in the striatum. The presence of such opposing pathways is seen in PGs working in other systems such as cardiovascular homeostasis and regulation of allergy (Kobayashi et al., 2004; Kunikata et al., 2005) .
One of the unique characteristics of the PGE 2 -EP 1 pathway is that this pathway modulates both D 1 and D 2 signaling positively. Given that there is a very low degree of overlap of D 1 and D 2 receptor in MSNs (Gerfen et al., 1990; Hersch et al., 1995) , and that EP 1 is present both in D 1 and D 2 neurons, it is most likely that the PGE 2 acts directly on EP 1 of each neuron type, either D 1 or D 2 , and augments its signaling. It is well known that D 1 and D 2 receptors have opposing actions on the activity of adenylyl cyclase: activation of D 1 receptors increases and that of D 2 receptors suppresses cAMP formation, and, consequently, Thr34 phosphorylation of DARPP-32 via PKA. Given that activation of EP 1 results in a rise in intracellular Ca 2ϩ ion (Watabe et al., 1993) and that a rise in intracellular Ca 2ϩ ion generally induces dephosphorylation of DARPP-32 Thr34 (Svenningsson et al., 2004) , the effects of EP 1 stimulation on D 1 and D 2 signaling cannot be readily explained by their signal transduction. An indication as to the mechanism of EP 1 action is the fact that effects of the EP 1 deficiency can be overridden by increasing concentration of agonists (Figs. 3, 4, 6 D) and that such an effect is seen also in the phenotype induced by an antagonist (Fig. 5) . These findings suggest that EP 1 may modulate ligand-binding activity of D 1 and D 2 receptors. One possibility is that intracellular Ca 2ϩ increase might affect desensitization of D 1 and D 2 receptors by suppressing G-protein-coupled receptor kinases as suggested previously for the D 1 receptor (Tiberi et al., 1996; Iacovelli et al., 1999 ). An alternative possibility is that EP 1 receptors may modulate D 1 and D 2 ligand binding via receptor-receptor interaction. It is known that D 2 receptors (Fuxe et al., 1998; Rocheville et al., 2000) interact physically with other GPCRs such as the adenosine A 2A receptor and the somatostatin SSTR5 receptor, and that heterooligomerization modulates ligand binding and signaling of the D 2 receptor. Similar oligomer formation may occur between EP 1 and D 1 and EP 1 and D 2 receptors to increase the binding affinities of the receptors for dopamine agonists and antagonists. This hypothesis may well explain the features of EP 1 action observed here. However, we failed to detect significant differences in binding properties of each type of dopamine receptor between wildtype and EP 1 -deficient mice. Careful examination of the change of ligand binding activity using heterologous expression systems may reveal modulation of D 1 and D 2 receptor binding by EP 1 .
Although we found in this study that EP 1 amplifies dopamine signaling, we previously reported that EP 1 deficiency increases dopamine turnover in the striatum and the frontal cortex, and that EP 1 apparently functions to suppress dopamine-dependent aggressive behavior . In our preliminary work, we found that EP 1 facilitates GABAergic neurotransmission in substantia nigra pars compacta and negatively modulates the activity of dopaminergic neurons (our unpublished observation). EP 1 may also function in the orbitofrontal cortex and amygdala, the brain areas implicated in controlling impulsive aggression (Davidson et al., 2000) . Localization of EP 1 in the latter was already reported (Matsuoka et al., 2003) . EP 1 might therefore have distinct effects on multiple dopaminoceptive areas, each of which mediate unique motor control, emotional, or cognitive functions.
If EP 1 does indeed regulate dopaminergic signaling differently at different sites, it would offer a pharmacological means to modulate various dopaminergic functions in unique patterns. For instance, EP 1 agonists may augment dopaminergic activity only in the striatum, thus possibly circumventing psychotic symptoms associated with classical Parkinson therapy using levodopa (Factor et al., 1995) . Similarly, treatment of schizophrenic patients with EP 1 agonists may suppress dopaminergic functions in the prefrontal cortex and limbic structures without extrapyramidal side effects, which still remain a common complication in antipsychotic therapy (Leucht et al., 2003) . Our findings have not only demonstrated that the PGE 2 -EP 1 pathway provides a modulatory mechanism of dopamine function in the striatum but also presented a novel strategic concept in development of drugs modulating dopaminergic pathways.
